TapewireFind a company

person · Reporting owner

Brenner Malcolm

Disclosed activity across 1 company

Tapewire entity
90162
SEC CIK
0001818068

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Kalaris Therapeutics, Inc.ALVR · Entity 6805DirectorJune 06, 2024June 07, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kalaris Therapeutics, Inc.

Report date June 06, 2024 · Filed June 07, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect100,197 Reported balance After 2024-06-06 transaction · row 1
1 source row

Row 1 · 2024-06-06 · Grant · Acquired 35,000 · Balance 100,197

F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan . Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Common StockSEC Table I · non-derivativeIndirectShares held by The Malcolm and Cliona Brenner Revocable Trust163,732 Reported balance Holding disclosure · report date 2024-06-06 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 163,732

F2: Shares held by The Malcolm and Cliona Brenner Revocable Trust, of which the Reporting Person is a trustee and settlor. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan . Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

F2: Shares held by The Malcolm and Cliona Brenner Revocable Trust, of which the Reporting Person is a trustee and settlor. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 06, 2024 Filed Jun 7, 2024 16:05 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantCommon Stock 35,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-070591 · ownership.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,197

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan . Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Read SEC document
May 11, 2023 Filed May 12, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantCommon Stock 35,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-029098 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,197

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
May 17, 2022 Filed May 19, 2022 16:27 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantStock Option (Right to Buy) · Derivative 27,500 $0.00 Strike: $4.60 $0.00
Disclosure

SEC source: 0000899243-22-018833 · doc4.xml · derivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,500

Underlying: Common Stock · 27,500 shares

Expires 2032-05-16

F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
May 25, 2021 Filed May 27, 2021 16:50 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantStock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $21.51 $0.00
Disclosure

SEC source: 0000899243-21-020866 · doc4.xml · derivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2031-05-24

F3 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
May 25, 2021 Filed May 27, 2021 16:50 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GiftCommon Stock 818,663 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-020866 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Shares held by Salt Free LP. On May 25, 2021, Salt Free LP distributed to its limited partners, pro rata and without consideration, 818,663 shares of the Issuer's common stock.The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F1 · ownership.nature: Shares held by Salt Free LP. On May 25, 2021, Salt Free LP distributed to its limited partners, pro rata and without consideration, 818,663 shares of the Issuer's common stock.The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 701 $34.40 $24,116.92
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 9

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 818,663

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.01 to $34.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 2,300 $33.31 $76,604.49
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 8

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 819,364

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.90 to $33.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 6,141 $32.19 $197,669.58
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 7

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 821,664

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.90 to $32.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 15,289 $31.27 $478,074.80
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 6

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 827,805

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.90 to $31.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 23,660 $30.39 $719,034.50
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 5

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 843,094

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.90 to $30.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 10,947 $37.41 $409,554.64
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 4

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 866,754

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.07 to $37.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,814 $36.58 $322,404.66
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 877,701

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.06 to $37.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 13,876 $35.46 $492,024.92
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 2

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 886,515

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.06 to $36.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 16:12 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 15,961 $34.67 $553,313.60
Disclosure

SEC source: 0001209191-21-018532 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 900,391

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $35.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 03, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,500 $38.53 $327,471.85
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 8

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 916,352

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.30 to $38.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 03, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 6,032 $37.73 $227,616.92
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 7

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 924,852

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.29 to $38.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 03, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,383 $36.91 $124,861.12
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 6

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 930,884

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.29 to $37.285. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,614 $39.14 $63,172.77
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 5

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 934,267

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.89 to $39.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 7,317 $38.27 $280,016.47
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 4

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 935,881

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.87 to $38.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,727 $37.35 $139,198.98
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 943,198

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.845 to $37.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,869 $39.00 $345,899.87
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 2

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 946,925

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.61 to $39.585. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 20:34 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 12,825 $38.39 $492,327.38
Disclosure

SEC source: 0001209191-21-017524 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 955,794

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.61 to $38.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 23, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 200 $41.19 $8,238.00
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 8

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 968,619

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.16 to $41.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 23, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,801 $40.40 $72,769.04
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 7

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 968,819

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.01 to $40.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 23, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,688 $39.46 $145,529.22
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 6

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 970,620

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.01 to $39.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 23, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 2,800 $38.75 $108,499.44
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 5

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 974,308

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.01 to $38.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 310 $43.38 $13,446.41
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 4

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 977,108

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.34 to $43.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,779 $42.80 $375,745.59
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 977,418

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.31 to $43.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 22, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 2,334 $41.58 $97,054.49
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 2

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 986,197

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.25 to $42.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 19, 2021 Filed Feb 23, 2021 19:42 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 11,990 $41.78 $500,935.01
Disclosure

SEC source: 0001209191-21-013481 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 988,531

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.31 to $42.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 08:38 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 2,982 $41.49 $123,731.83
Disclosure

SEC source: 0000899243-21-007328 · doc4.xml · nonDerivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,000,521

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.85 to $41.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 08:38 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 2,800 $40.34 $112,950.04
Disclosure

SEC source: 0000899243-21-007328 · doc4.xml · nonDerivative · entry 2

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,003,503

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.85 to $40.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 18, 2021 Filed Feb 19, 2021 08:38 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 975 $39.68 $38,683.91
Disclosure

SEC source: 0000899243-21-007328 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,006,303

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.83 to $39.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 17, 2021 Filed Feb 18, 2021 21:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 200 $41.99 $8,398.00
Disclosure

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 7

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,007,278

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 17, 2021 Filed Feb 18, 2021 21:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 2,765 $41.29 $114,168.51
Disclosure

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 6

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,007,478

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.89 to $41.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 17, 2021 Filed Feb 18, 2021 21:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,000 $39.97 $39,966.00
Disclosure

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 5

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,010,243

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.60 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 17, 2021 Filed Feb 18, 2021 21:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,200 $38.66 $46,392.72
Disclosure

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 4

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,011,243

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.16 to $39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 16, 2021 Filed Feb 18, 2021 21:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 100 $43.13 $4,313.00
Disclosure

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,012,443

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 16, 2021 Filed Feb 18, 2021 21:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,000 $42.25 $42,249.50
Disclosure

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 2

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,012,543

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.10 to $42.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
February 16, 2021 Filed Feb 18, 2021 21:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,120 $41.75 $213,769.22
Disclosure

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,013,543

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.10 to $42.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 21:55 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionSeries A-3 Convertible Preferred Stock · Derivative 1,518,018 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021586 · doc4.xml · derivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,018,663 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · price: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 21:55 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionCommon Stock 1,018,663 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021586 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,018,663

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2020 Filed Jul 31, 2020 18:35 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantStock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0000899243-20-020913 · doc4.xml · derivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-07-29

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) July 29, 2021, and (b) the next annual meeting of the Issuer's stockholders.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.